The impact of blood shear rate on arterial thrombus formation

Future Science OA

Volumn 1, Issue 4, 2015, Pages

  Sakariassen, Kjell S ^a   Orning, Lars ^b   Turitto, Vincent T ^c  

^a KellSa sas   (Italy)

^b Alere Technologies AS   (Norway)

^c ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

arterial stenosis; platelet activation; platelet adhesion; platelet aggregation; shear rate; shear stress

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; ARGINYLGLYCYLASPARTYLSERINE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; CLOPIDOGREL; COLLAGEN TYPE 3; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; FLUINDIONE; HEPARIN; HIRUDIN; LAMIFIBAN; LINOTROBAN; LIPOCORTIN 5; NADROPARIN; THROMBIN; THROMBOCYTE RECEPTOR; THROMBOPLASTIN; TICLOPIDINE; VITAMIN K GROUP; WARFARIN;

ARTERY THROMBOSIS; BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; BLOOD PERFUSION CHAMBER; BLOOD VISCOSITY; CARDIOVASCULAR RISK; DRUG EFFICACY; HUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SHEAR RATE; SHEAR STRESS; THROMBOCYTE ACTIVATION; VASCULAR EQUIPMENT; VON WILLEBRAND DISEASE;

EID: 85012091020     PISSN: None     EISSN: 20565623     Source Type: Journal    
DOI: 10.4155/fso.15.28     Document Type: Review

References (56)

1. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc. Res. 5, 167-179 (1973).
2. Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. 1. Shear-dependant decrease of adhesion in von Willebrand's ddisease and the Bernard-Soulier syndrome. J. Lab. Clin. Med. 92, 750-764 (1978).
3. Baumgartner HR, Sakariassen KS. Factors controlling thrombus formation on arterial lesions. Ann. NY Acad. Sci. 454, 162-177 (1985).
4. Sakariassen KS, Hanson SR, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb. Res. 104, 149-174 (2001).
5. Sakariassen KS, Turitto VT, Baumgartner. Recollections of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood. J. Thromb. Haemost. 2, 1681-1690 (2004).
6. Roux SP, Sakariassen KS, Turitto VT et al. Effect of aspirin and epinephrine on experimentally-induced thrombogenesis in dogs: a parallelism between in vivo and ex vivo thrombosis models. Arterioscler. Thromb. 11, 1182-1191 (1991).
7. Strony J, Beaudin A, Brands D et al. Analysis of shear stress and hemodynamic factors in a model of artery stenosis and thrombosis. Am. J. Physiol. 265, H1787-H1796 (1993).
8. Hutchison KJ, Karpinski E. In vivo demonstration of flow recirculation and turbulence downstream of graded stenoses in canine arteries. J. Biomech. 18(4), 285-296 (1985).
9. Aarts PA, van den Broek SA, Prins GW et al. Blood platelets are concentrated near the wall and red blood cells in the center in flowing blood. Arteriosclerosis 8(6), 819-824 (1988).
10. Turitto VT. Blood viscosity, mass transport, and thrombogenesis. In:Progress In Hemostasis And Thrombosis. Spaet TM (Ed.). Grune & Stratton, NY, USA 5, 139-174 (1981).
11. Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and hemostasis: basic principles and applications. Thromb. Haemost. 55, 415-435 (1986).
12. Sakariassen KS, Fressinaud E, Girma JP et al. Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen. Ann. NY Acad. Sci. 516, 52-65 (1987).
13. Orvim U, Barstad RM, Vlasuk GP et al. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of human shear dependent thrombus formation. Arterioscler. Thromb. Vasc. Biol. 15, 2188-2194 (1995).
14. Sakariassen KS, Aarts PAMM, de Groot PG et al. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J. Lab. Clin. Med. 102, 522-535 (1983).
15. Sakariassen KS, Joss R, Muggli R et al. Collagen type III induced ex vivo thrombogenesis in humans. Role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 10(2), 276-284 (1990).
16. Orvim U, Roald HE, Stephens RW et al. Tissue factorinduced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions. Arterioscler. Thromb. 14(12), 1976-1983 (1994).
17. Aznar-Salatti J, Anton P, Nemerson Y et al. Modulation of procoagulant activity of extracellular endothlial matrix by anti-tissue factor and the synthetic peptide arg-gly-asp-val. Experiments with flowing non-antigoaulated blood. Blood Coag. Fibrinol. 4(6), 881-890 (1993).
18. Diquelou A, Dupouy D, Gaspin D et al. Relationship between endothelial tissue factor and thrombogenesis under blood flow conditions. Thromb. Haemost. 74(2), 778-783 (1995).
19. Sakariassen KS. Thrombus formation on apex of arterial stenoses: the need for a fluid high shear diagnosis device. Future Cardiol. 3(2), 193-201 (2007).
20. Sakariassen KS, Kuhn H, Muggli R et al. Growth and stability of thrombi in flowing citrated blood: assessment of plateletsurface interactions with computer-assisted morphometry. Thromb. Haemost. 60(33), 392-398 (1988).
21. Orvim U, Barstad M, Stormorken H et al. Immunological quantification of fibrin deposition in thrombi formed in flowing native blood. Brit. J. Haematol. 95, 389-398 (1996).
22. Bossavy JP, Sakariassen KS, Barret A et al. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemost. 79, 162-168 (1998).
23. Barstad RM, Roald HE, Cui Y et al. A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native human blood at the apex of well-defined stenoses. Arterioscler. Thromb. 14(12), 1984-1991 (1994).
24. Baumgartner HR, Sakariassen KS. Factors controlling thrombus formation on arterial lesions. Ann. NY Acad. Sci. 454, 162-177 (1985).
25. Barstad RM, Kierulf P, Sakariassen KS. Collagen-induced thrombus formation at the apex of eccentric stenoses. A time-course study with non-anticoagulated blood. Thromb. Haemost. 75(5), 685-692 (1996).
26. Weiss HJ, Turitto VT, Baumgartner HR. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib and storage granules. Blood 67, 322-330 (1986).
27. Weiss HJ, Turitto VT, Baumgartner HR. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. J. Clin. Invest. 78, 1072-1082 (1986).
28. Fressinaud E, Sakariassen KS, Rothschild C et al. Sheardependent impairment of thrombus growth on collagen in non-anticoagulated blood from patients with von Willebrand disease and Hemophilia A. Blood 80, 988-994 (1992).
29. Barstad RM, Orvim U, Hamers MJAG et al. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb. Haemost. 75, 827-832 (1996).
30. Cadroy Y, Sakariassen KS, Charlet JP et al. Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood 98 1097-1103 (2001).
31. Barstad RM, Stormorken H, Orning L et al. Reduced thrombus formation in native blood of homozygous factor VII deficient patients at high arterial wall shear rate. Blood 84, 3371-3377 (1994).
32. Sakariassen KS, Barstad RM. Mechanisms of thrombus formation at arterial plaques. Blood Coag. Fibrinol. 4, 615-625 (1993).
33. Veen G, Meyer A, Verheugt FW et al. Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the prevention of reocclusion in coronary thrombolysis. J. Am. Coll. Cardiol. 22, 1755-1762 (1993).
34. Bossavy JP, Thalamas C, Sagnard L et al. A doubleblind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin and ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 92, 1518-1525 (1998).
35. Roald HE, Barstad RM, Kierulf P et al. Clopidogrel -a platelet inhibitor which inhibits thrombogenesis in human non-anticoagulated blood independently of the blood flow conditions. Thromb. Haemost. 71, 665-672 (1994).
36. Roald HE, Barstad RM, Engen A et al. HN-1150 -a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb. Haemost. 71, 103-109 (1994).
37. Kirchhofer D, Tschopp TB, Steiner B et al. Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Blood 86, 3815-3822 (1995).
38. Cadroy Y, Bossavy JP, Thalamas C et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 101, 2823-2828 (2000).
39. Cadroy Y, Thalamas C, Sakariassen KS et al. Superior efficacy of clopidogrel plus acetylsalicyclic acid compared with extended-release dipyridamole plus acetylsalicyclic acid in preventing arterial thrombosis in healthy volunteers. Thromb. Res. 116, 293-300 (2005).
40. Harker LA, Kadatz RA. Mechanism action of dipyridamole. Thromb. Res. 29(1), 39-46 (1983).
41. Terpening C. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. J. Am. Board Fam. Med. 22(1), 51-56 (2009).
42. Halkes PH, van Gijn J, Kapelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 367, 1665-1673 (2006).
43. Diquelou A, Dupouy D, Cariou R et al. A comparative study of the anticoagulant and antithrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis. Thromb. Haemost. 74, 1286-1292 (1995).
44. Kirchhofer D, Tschopp TB, Baumgartner HR. Active siteblocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler. Thromb. Vasc. Biol. 15, 1098-1106 (1995).
45. Bossavy JP, Sakariassen KS, Thalamas C et al. Antithrombotic efficacy of the Vitamin K antagonist fluinidone in a human ex vivo model of arterial thrombosis. Effect of anticoagulation level and combination therapy with aspirin. Arterioscler. Thromb. Vasc. Biol. 19, 2269-2275 (1999).
46. Bossavy JP, Sakariassen KS, Rubsamen K et al. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human model of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 19, 1348-1353 (1999).
47. Kirchhofer D, Tschopp TB, Hadvary P et al. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. J. Clin. Invest. 93, 2073-2083 (1994).
48. Orvim U, Barstad RM, Orning L et al. Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood. Arterioscler. Thromb. Vasc. Biol. 17, 3049-3056 (1997).
49. Orning L, Fischer PM, Hu CK et al. A cyclic pentapeptide derived from the EGF-2 like domain of factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation. Thromb. Haemost. 87, 13-21 (2002).
50. Lindahl AK, Sandset PM, Thune-Wiger M et al. Tissue factor pathway inhibitor prevents fibrin deposition on procoagulant subendothelial matrix when exposed to flowing non-anticoagulated human blood. Blood Coag. Fibrinol. 5, 755-760 (1994).
51. van Heerde WL, Sakariassen KS, Hemker HC et al. Annexin V inhibits the procoagulant activity of TNF-stimulated endothelial cells under flow conditions. Arterioscler. Thromb. 14, 824-830 (1994).
52. Barstad RM, Hamers MJAG, Stephens RW et al. Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa dependent thrombus formation. Blood 86, 212-218 (1995).
53. Sakariassen KS. Blood flow devices in medical research and clinical testing in humans: are we approaching personalized medicine? Future Cardiol. 3(1), 71-90 (2007).
54. Zwaginga JJ, Nash G, King MR et al. Flow-based assays for global assessment of hemostasis. Part 1: biorheological considerations. J. Thromb. Haemost. 4, 2486-2487 (2006).
55. Zwaginga JJ, Sakariassen KS, Nash G et al. Flow-based assays for global assessment of hemostasis. Part 2: current methods and considerations for the future. J. Thromb. Haemost. 4, 2716-2717 (2006).
56. Roest M, Reininger A, Zwaginga JJ et al. Flow chamberbased assays to measure thrombus formation in vitro: requirements for standardization. J. Thromb. Haemost. 9, 2322-2324 (2011).